The FDA continues to update its list of off-patent, off-exclusivity drugs without approved generic competitors to meet the organization's broader goals defined under the Drug Competition Action Plan.
On June 26, 2018, the FDA updated its list of off-patent, off-exclusivity drugs without approved generic competitors to include new drug products and an appendix that identifies new drug application (NDA) products that were removed from the list because one or more abbreviated new drug applications (ANDAs) referencing such NDA drug products have been approved since the previous list publication.
The FDA maintains the list to encourage the development and submission of generic drug ANDAs in markets with little competition and improve transparency. The appendix now lists 11 drugs that previously did not have an approved generic despite the expiry of the reference product’s patents and exclusivity.
There are 2 parts of the list, one listing drugs for which FDA could immediately accept an ANDA without prior discussion, and another that lists drugs with potential legal, regulatory, or scientific issues that would need to be addressed before an ANDA submission. Part 2 includes biological products that are subject to the transition provisions described in the Biologics Price Competition and Innovation Act of 2009.
The list excludes any NDA drugs that have been approved within the past year because it generally is too soon for an ANDA referencing such a product to have been approved, according to an FDA statement.
The FDA first published the list in June 2017 as part of FDA Commissioner Scott Gottlieb’s push to bring more price competition to the market and eliminate a backlog of generic drug applications. The list was updated in December 2017, and added new drugs and reorganized the list based on drug product rather than active ingredients. Additionally, the agency added information about the dosage form for each drug. FDA will update the list every 6 months.
The publication and updating of the list of off-patent, off-exclusivity drugs without approved generic competitors is one step in Commissioner Gottlieb’s Drug Competition Action Plan, which is designed to address what he sees as delays in the approvals of generic drugs by some drug makers who seek to “game” the regulatory system.
According to Rachel Schwartz, director of communications for the Association for Accessible Medicines, the main barrier to developing generics for these products is manufacturing related, as more complex products “require specialty manufacturing processes and facilities” that many generic drug manufacturers do not currently possess.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.